Please provide your email address to receive an email when new articles are posted on . Lesional and distal, nonlesional areas stratified by disease severity and not by the presence of systemic ...

Psoriasis, a chronic inflammatory skin condition characterized by dry and scaly skin lesions, affects about 7.5 million people in the United States. Psoriasis results from abnormal proliferation of ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers reviewed existing data on psoriasis etiopathogenesis and treatment. Psoriasis is a prevalent, chronic, ...

SAN DIEGO -- Short-term, high-dose treatment with risankizumab (Skyrizi) induced long-term control of plaque psoriasis in association with eradication of resident memory T cells (T RM), a small ...

Soumya Chakravarty, MD, PhD, FACP, FACR, strategic lead of the Rheumatology Therapeutic Area at Janssen, discussed the interlinked pathophysiology of psoriasis and psoriatic arthritis, and the ...

Some psoriasis treatments may modify the underlying disease in ways that go beyond their direct pharmacological effects. The controversial idea of disease modification is the subject of a review that ...

According to the investigator, these findings further support psoriasis as a systemic inflammatory disease. The analysis included 15 observational studies comprising 200,000 patients with psoriasis ...

Philadelphia, August 10, 2022 – Psoriasis is a chronic inflammatory, debilitating skin disorder. Although there is no cure for psoriasis, several treatment options can inhibit inflammation and relieve ...

Please provide your email address to receive an email when new articles are posted on . PASI 100 was achieved by one-third of patients receiving zasocitinib 30 mg at week 12. While more adverse events ...

PARIS — Clinicians should consider treating their patients with psoriasis with GLP-1 receptor agonists (RAs), when appropriate, as these drugs appear to confer considerable additional benefits beyond ...